NetworkNewsBreaks – India Globalization Capital,
Post# of 430
(Total Views: 1209)
Posted On: 12/07/2017 5:44:49 PM
NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Launches Pharmaceutical Cannabinoid Pipeline Websites
India Globalization Capital (NYSE American: IGC) this morning announced the launching of two new websites (www.IGCPharma.com and www.Hyalolex.com) to detail its initiatives, development timeline and pipeline of pharmaceutical cannabinoids for use in treatment of the symptoms of Alzheimer’s disease, pain, seizures and other health-related issues. Ram Mukunda, CEO of IGC, indicated in the news release that Alzheimer’s is IGC’s initial focus on the canna-pharmaceutical front and that the company’s near-term goal is to commercialize its Alzheimer’s liquid formulation as a Complimentary and Alternative Medicine (“CAM”) and sell the product through licensed medical cannabis dispensaries in the U.S., Canada and Germany. Mukunda indicated that longer-term goals include moving IGC’s Alzheimer’s formulation through FDA registered pre-clinical and clinical trials. IGC also has six provisional patent filings for phytocannabinoid-based combination therapy for the indications of pain, medical refractory epilepsy, and cachexia. Further, in May 2017, IGC acquired exclusive rights to a University of South Florida Research Foundation filed patent entitled, “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
India Globalization Capital (NYSE American: IGC) this morning announced the launching of two new websites (www.IGCPharma.com and www.Hyalolex.com) to detail its initiatives, development timeline and pipeline of pharmaceutical cannabinoids for use in treatment of the symptoms of Alzheimer’s disease, pain, seizures and other health-related issues. Ram Mukunda, CEO of IGC, indicated in the news release that Alzheimer’s is IGC’s initial focus on the canna-pharmaceutical front and that the company’s near-term goal is to commercialize its Alzheimer’s liquid formulation as a Complimentary and Alternative Medicine (“CAM”) and sell the product through licensed medical cannabis dispensaries in the U.S., Canada and Germany. Mukunda indicated that longer-term goals include moving IGC’s Alzheimer’s formulation through FDA registered pre-clinical and clinical trials. IGC also has six provisional patent filings for phytocannabinoid-based combination therapy for the indications of pain, medical refractory epilepsy, and cachexia. Further, in May 2017, IGC acquired exclusive rights to a University of South Florida Research Foundation filed patent entitled, “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)IGC Pharma Inc. (IGC) Stock Research Links
Scroll down for more posts ▼